ClinicalTrials.gg
TerminatedNCT00583557Updated Aug 7, 2013Results posted

A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01

A Phase 2 interventional study of belimumab in Rheumatoid Arthritis, sponsored by Human Genome Sciences Inc.. Terminated at 48 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-07.

Sponsored by Human Genome Sciences Inc. (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision - not related to safety

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
155
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Arthritis, Rheumatoid by GlaxoSmithKline — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · GlaxoSmithKline.

Enrollment
11th of 40
155 · median 52
Started
2005
with 7 others
Phase 2
17 of 44
none open now
Registered
18th of 44
by date

Among the 44 studies in Arthritis, Rheumatoid by GlaxoSmithKline, this one is the 11th largest by enrollment of the 40 interventional ones that give a count, is one of 8 that started in 2005, is one of 17 in phase 2, and was the 18th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

1 of the 44 studies in Arthritis, Rheumatoid by GlaxoSmithKline is open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Arthritis, Rheumatoid by GlaxoSmithKline, or all of them as a file.
02

Study summary

This is a continuation trial of LymphoStat-B™ to evaluate the long-term safety in subjects with Rheumatoid Arthritis that completed study LBRA01 and benefitted from treatment.

Read the detailed description

This is a multi-center, open label, continuation trial of LymphoStat-B™ in Rheumatoid Arthritis (RA) subjects who achieved at least an ACR20 response in the Phase 2 study LBRA01 (NCT00071812).

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
  • RA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Primary Inclusion Criteria:

  1. Have completed the LBRA01 trial.
  2. Have achieved at least an ACR20 response at the end of LBRA01.

Primary Exclusion Criteria:

  1. Have switched NSAIDs due to worsening RA disease activity, used more than 10 mg/day of oral prednisone, or were given a injection during the last 30 days of LBRA01.
  2. Required a new DMARD (not otherwise excluded in protocol LBRA01) to replace an ineffective one, or an additional DMARD (not to exceed 2 DMARDs in total) within the last 60 days of LBRA01.
  3. Used prohibited medications during their participation in LBRA01. These medications include the following:

    • Other agents.
    • Biologic response modifiers
    • Cyclophosphamide.
    • Corticosteroid injections (except 1 injection of up to 40 mg of prednisone into an inflamed joint or intramuscularly every 6 months).
    • 2 new DMARDs.
    • 1 new DMARD plus high dose prednisone >10 mg/day.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
155 participants (actual)

Study arms

  • Experimental
    Belimumab

    Drug: belimumab

Interventions

  • IV 10mg/kg Q28 days

    Also known as: LymphoStat-B™

06

What researchers measure

Primary outcomes

  1. To Evaluate the Long-term Safety of LymphoStat-B™ in Subjects With RA.

    SEE ALSO ADVERSE EVENT (AE) RESULTS SECTION.

    Time frame: Up to 5 years

Secondary outcomes

  1. The Efficacy Endpoints Will Include Long-term ACR Responses, DAS28 Response, C-reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), and Rheumatoid Factor (RF).

    NOT ANALYZED

    Time frame: up to 5 Years

07

Results

Posted Jun 29, 2011

Participant flow

Participant flow — Overall Study
MilestoneBelimumab 10 mg/kg
Started155
Received at least 1 dose belimumab153
Completed85
Not completed70
Withdrew: Withdrawal by subject18
Withdrew: Adverse event9
Withdrew: Lack of efficacy31
Withdrew: Lack of compliance5
Withdrew: Other5
Withdrew: Did not receive belimumab in lbra992

Outcome measures

PrimaryTo Evaluate the Long-term Safety of LymphoStat-B™ in Subjects With RA.

SEE ALSO ADVERSE EVENT (AE) RESULTS SECTION.

Time frame:
Up to 5 years
Reported as:
Number · Particpants
To Evaluate the Long-term Safety of LymphoStat-B™ in Subjects With RA.
ParticpantsBelimumab 10 mg/kg
Number of subjects with at least 1 AE148
Number of subjects with at least 1 Non-Serious AE144
Number of subjects with at least 1 Serious AE47
Number of subjects with an AE resulting in death3
SecondaryThe Efficacy Endpoints Will Include Long-term ACR Responses, DAS28 Response, C-reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), and Rheumatoid Factor (RF).

NOT ANALYZED

Time frame:
up to 5 Years

Results for this outcome have not been posted.

Adverse events

Collected over Up to 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belimumab 10 mg/kg—47/153 (30.7%)144/153 (94.1%)
Most frequent serious events
Showing 10 of 87
Most frequent serious events
EventBelimumab 10 mg/kg
OsteoarthritisMusculoskeletal and connective tissue disorders6/153
AnaemiaBlood and lymphatic system disorders3/153
Angina pectorisCardiac disorders3/153
PneumoniaInfections and infestations3/153
ArthralgiaMusculoskeletal and connective tissue disorders3/153
Coronary artery diseaseCardiac disorders2/153
Non-cardiac chest painGeneral disorders2/153
GastroenteritisInfections and infestations2/153
PyelonephritisInfections and infestations2/153
DehydrationMetabolism and nutrition disorders2/153
Most frequent other events
Showing 10 of 46
Most frequent other events
EventBelimumab 10 mg/kg
ArthralgiaMusculoskeletal and connective tissue disorders66/153
Upper respiratory tract infectionInfections and infestations53/153
SinusitisInfections and infestations39/153
Pain in extremityMusculoskeletal and connective tissue disorders36/153
BronchitisInfections and infestations35/153
Back painMusculoskeletal and connective tissue disorders31/153
Oedema peripheralGeneral disorders28/153
CoughRespiratory, thoracic and mediastinal disorders27/153
DiarrhoeaGastrointestinal disorders24/153
Joint swellingMusculoskeletal and connective tissue disorders24/153

Baseline characteristics

Age Continuous
Age Continuous(years)Belimumab 10 mg/kg
Mean51.1 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Belimumab 10 mg/kg
Female118
Male35
08

Study locations

48 sites
  • Univ of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Arizona Arthritis Research
    Paradise Valley, Arizona 85253, United States
  • Arthritis Health
    Scottsdale, Arizona 85260, United States
  • The University of Arizona Health Sciences Center
    Tucson, Arizona 85724, United States
  • University of Southern CA
    Los Angeles, California 90033, United States
  • Wallace Rheumatic Disease Center
    Los Angeles, California 90048, United States
  • Boling Clinical Trials
    Rancho Cucamonga, California 91730, United States
  • Arthritis Care Center, Inc.
    San Jose, California 95126, United States
  • Arthritis Associates & Osteoporosis Center of Colorado Springs
    Colorado Springs, Colorado 80910, United States
  • Washington Hospital Center
    Washington, DC, District of Columbia 20010, United States
  • Arthritis and Rheumatic Disease Specialties
    Aventura, Florida 33180, United States
  • Rheumatology Associates of Central Florida
    Orlando, Florida 32806, United States
  • Tampa Medical Group, P.A.
    Tampa, Florida 33614, United States
  • Radiant Research Boise
    Boise, Idaho 83704, United States
  • Rheumatology Associates
    Chicago, Illinois 60612, United States
  • Medical Specialists
    Munster, Indiana 46321, United States
  • Kentuckiana Center for Better Bone and Joint Health
    Louisville, Kentucky 40202, United States
  • The Osteoporosis and Arthritis Clinical Trial Center
    Cumberland, Maryland 21502, United States
  • Center for Rheumatology and Bone Research
    Wheaton, Maryland 20902, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University in St. Louis
    St. Louis, Missouri 63110, United States
  • Arthritis Center of Nebraska
    Lincoln, Nebraska 68506, United States
  • Strafford Medical Associates, P.A.
    Dover, New Hampshire 03820, United States
  • The Center for Rheumatology
    Albany, New York 12206, United States
  • North Shore University Hospital
    Manhasset, New York 11030, United States
  • Arthritis Clinic and Carolina Bone and Joint
    Charlotte, North Carolina 28210, United States
  • Wake Forest Unviersity School of Medicine
    Winston-Salem, North Carolina 27599-7280, United States
  • Bone and Joint Hospital - Research Department
    Oklahoma City, Oklahoma 73103, United States
  • Oklahoma Medical Reseach Foundation
    Oklahoma City, Oklahoma 74114, United States
  • Oklahoma Center for Arthritis Therapy & Research
    Tulsa, Oklahoma 74114, United States
  • University of Pittsburgh School of Medicine & ASPH
    Pittsburgh, Pennsylvania 15261, United States
  • Rheumatic Disease Associates
    Willow Grove, Pennsylvania 19090, United States
  • Arthritis Centers of Texas
    Dallas, Texas 75246, United States
  • UT Southwestern Medical Center at Dallas
    Dallas, Texas 75390-8884, United States
  • Houston Institute for Clinical Research
    Houston, Texas 77074, United States
  • Texas Research Center
    Sugar Land, Texas 77479, United States
  • IPC Clinical Research
    Ogden, Utah 84403, United States
  • Arthritis Clinic of Northern Virginia, P.C.
    Arlington, Virginia 22205, United States
  • Seattle Arthritis Clinic
    Seattle, Washington 98133, United States
  • Arthritis Northwest Rheumatology
    Spokane, Washington 99204, United States
  • Rheumatology Northwest Clinical Trials
    Yakima, Washington 98902, United States
  • Rheumatic Disease Center
    Glendale, Wisconsin 53217, United States
  • Gundersen Clinic, LTD
    La Crosse, Wisconsin 54610, United States
  • Marshfield Medical Research Foundation
    Wausau, Wisconsin 54401, United States
  • NZOZ Centrum Medyczne
    Bialystok, Poland
  • Wojewodzki Zespol Reumatologiczny
    Sopot, Poland
  • Instytut Reumaologii
    Warszawa, Poland
  • Instytut Reumatologii
    Warszawa, Poland
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2007
First posted
Dec 31, 2007
Start
Jan 2005
Primary completionActual
Nov 2009
CompletionActual
Nov 2009
Results first posted
Jun 29, 2011
Last update
Aug 7, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00583557
Responsible party
Sponsor
First posted
Dec 31, 2007
Start date
Jan 2005
Primary completion
Nov 2009
Completion
Nov 2009
Results posted
Jun 29, 2011
Last update
Aug 7, 2013

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion